Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 442,988
  • Shares Outstanding, K 36,732
  • Annual Sales, $ 1,720 K
  • Annual Income, $ -67,480 K
  • 60-Month Beta 1.21
  • Price/Sales 247.16
  • Price/Cash Flow N/A
  • Price/Book 4.92
Trade MRNS with:

Options Overview

Details
  • Implied Volatility 71.35%
  • Historical Volatility 54.44%
  • IV Percentile 24%
  • IV Rank 12.92%
  • IV High 240.10% on 09/25/20
  • IV Low 46.32% on 06/07/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 38
  • Volume Avg (30-Day) 240
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,929
  • Open Int (30-Day) 2,019

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.61
  • Number of Estimates 6
  • High Estimate 0.06
  • Low Estimate -0.76
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -19.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.71 +12.59%
on 08/18/21
12.79 -5.71%
on 09/02/21
+0.02 (+0.17%)
since 08/17/21
3-Month
10.71 +12.59%
on 08/18/21
19.83 -39.18%
on 06/25/21
-6.08 (-33.52%)
since 06/17/21
52-Week
10.61 +13.67%
on 09/24/20
20.04 -39.82%
on 03/10/21
-0.80 (-6.22%)
since 09/17/20

Most Recent Stories

More News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards...

MRNS : 12.06 (+4.33%)
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal...

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that members of its leadership...

MS : 101.75 (-0.70%)
MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

--Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

RADNOR, Pa. (AP) _ Marinus Pharmaceuticals Inc. (MRNS) on Tuesday reported a loss of $23.8 million in its second quarter.

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today provided an update on its clinical and regulatory...

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards...

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial...

MRNS : 12.06 (+4.33%)
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

--Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion's expertise in rare orphan diseases, antiepileptics and European commercialization...

MRNS : 12.06 (+4.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical...

See More

Key Turning Points

3rd Resistance Point 13.25
2nd Resistance Point 12.69
1st Resistance Point 12.38
Last Price 12.06
1st Support Level 11.51
2nd Support Level 10.95
3rd Support Level 10.64

See More

52-Week High 20.04
Fibonacci 61.8% 16.44
Fibonacci 50% 15.33
Fibonacci 38.2% 14.21
Last Price 12.06
52-Week Low 10.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar